Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
Reungwetwattana T, Cho BC, Lee KH, Pang YK, Fong CH, Kang JH, Lee YG, Lim CS, Danchaivijitr P, Lim YN, Lee Y, How SH, Geater S, Lee SS, Min YJ, Kim JH, Lee JS, Lee GW, Soo RA, Lee SY, Choi S, Ahn MJ. Reungwetwattana T, et al. Among authors: pang yk. J Thorac Oncol. 2023 Oct;18(10):1351-1361. doi: 10.1016/j.jtho.2023.06.016. Epub 2023 Sep 11. J Thorac Oncol. 2023. PMID: 37702629 Free article. Clinical Trial.
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
Soo RA, Cho BC, Kim JH, Ahn MJ, Lee KH, Zimina A, Orlov S, Bondarenko I, Lee YG, Lim YN, Lee SS, Lee KH, Pang YK, Fong CH, Kang JH, Lim CS, Danchaivijitr P, Kilickap S, Yang JC, Arslan C, Lee H, Park SN, Cicin I. Soo RA, et al. Among authors: pang yk. J Thorac Oncol. 2023 Dec;18(12):1756-1766. doi: 10.1016/j.jtho.2023.08.017. Epub 2023 Oct 22. J Thorac Oncol. 2023. PMID: 37865896 Free article. Clinical Trial.
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S; KEYNOTE-671 Investigators. Spicer JD, et al. Lancet. 2024 Sep 28;404(10459):1240-1252. doi: 10.1016/S0140-6736(24)01756-2. Epub 2024 Sep 14. Lancet. 2024. PMID: 39288781 Clinical Trial.
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Wakelee H, et al. N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3. N Engl J Med. 2023. PMID: 37272513 Free PMC article. Clinical Trial.
Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer.
Poh ME, Balakrishnan S, Tan SN, Zainal Abidin MA, Liam CK, Tan JL, Pang YK, Alaga A, Tho LM, How SH. Poh ME, et al. Among authors: pang yk. Transl Lung Cancer Res. 2024 Jul 30;13(7):1649-1659. doi: 10.21037/tlcr-24-243. Epub 2024 Jul 23. Transl Lung Cancer Res. 2024. PMID: 39118879 Free PMC article.
Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial.
Paton NI, Gurumurthy M, Lu Q, Leek F, Kwan P, Koh HWL, Molton J, Mortera L, Naval S, Bakar ZA, Pang YK, Lum L, Lim TK, Cross GB, Lekurwale G, Choi H, Au V, Connolly J, Hibberd M, Green JA; Pascolizumab Tuberculosis Trial Team. Paton NI, et al. Among authors: pang yk. J Infect Dis. 2024 Sep 23;230(3):590-597. doi: 10.1093/infdis/jiae104. J Infect Dis. 2024. PMID: 38527849 Clinical Trial.
Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?
Poh ME, Chai CS, Liam CK, Ho GF, Pang YK, Hasbullah HH, Tho LM, Muhamad Nor I, Ho KF, Thiagarajan M, Samsudin A, Omar A, Ong CK, Soon SY, Tan SN, How SH. Poh ME, et al. Among authors: pang yk. Transl Lung Cancer Res. 2024 Feb 29;13(2):307-320. doi: 10.21037/tlcr-23-691. Epub 2024 Feb 28. Transl Lung Cancer Res. 2024. PMID: 38496703 Free PMC article.
Developing a home-based pulmonary rehabilitation programme for patients with chronic respiratory diseases in Malaysia: A mixed-method feasibility study.
Chan SC, Patrick Engksan J, Jeevajothi Nathan J, Sekhon JK, Hussein N, Suhaimi A, Hanafi NS, Pang YK, Mohamad Yatim S, Habib GMM, Pinnock H, Khoo EM; RESPIRE Collaboration. Chan SC, et al. Among authors: pang yk. J Glob Health. 2023 Oct 27;13:04099. doi: 10.7189/jogh.13.04099. J Glob Health. 2023. PMID: 37883199 Free PMC article.
100 results